The system reviews notes as they are completed and looks for documentation gaps, timing risks and eligibility signals that deserve attention.
The purpose is simple: help reviewers find the charts that need them most. The system reads continuously, raises specific concerns and preserves a clear audit trail. It does not determine eligibility, finalize documentation or make decisions about care.
The system fits around the documentation your team already creates. It performs the first pass, then sends specific issues to a HospiceMD reviewer who confirms, dismisses or escalates them.
Each completed note is checked against the documentation elements a hospice reviewer would normally look for. The system identifies possible gaps and patterns, then routes them to a clinician for confirmation before any action is recommended.
The system keeps the relevant dates, chart signals and documentation requirements visible throughout the episode. When something appears inconsistent or time sensitive, a reviewer receives the chart context and decides whether intervention is needed.
When appropriate, the system can prepare a decline focused narrative starter from the documented visit. A HospiceMD reviewer then checks it against the chart, corrects the language and decides whether it is ready for use. Nothing is placed into the record without human approval.
We will walk through the connection, first pass review, clinician confirmation and audit trail using the documentation patterns your agency already manages. You will see exactly what the system can do and where the human reviewer remains in control.
Clinical automation is only useful when the boundaries are clear. Human approval, auditability and data protection are part of the workflow from the beginning.
No flag, draft or eligibility related conclusion is treated as final until a HospiceMD reviewer confirms it.
The record shows what the system surfaced, what the reviewer decided, what changed and when the action occurred.
Each engagement operates under a signed Business Associate Agreement with access limited to the approved workflow.
Agency data remains within the engagement and is not used to train public or shared models.
Enter the number of charts reviewed each week, the average time spent on manual first pass QA and the reviewer cost. The estimate shows how much time may be redirected toward confirmed risks, coaching and deeper clinical review.
redirected each week toward confirmed risks and deeper clinical review, about $22,464 a year in reviewer time.
Illustrative estimate only. Actual time savings depend on chart complexity, workflow design, review standards and the proportion of findings requiring human follow up.
Healthy skepticism is appropriate when technology touches clinical documentation. These answers explain where the system helps, where the human reviewer remains responsible and how the work is recorded.
The system does not make the decision for us, which was my biggest concern. It helps us find the chart, then our reviewer looks at the full context and signs off.
Our team spends less time reading routine notes and more time on the records that actually need judgment. The workflow feels more focused without lowering the standard.
We caught a closing window early enough to address it. The alert was useful because it came with the chart context and still required a clinician to decide what happened next.